Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

Cancer

Volumn 95, Issue 2, 2002, Pages 361-376

  Samson, David J ^a   Seidenfeld, Jerome ^a   Schmitt, Brian ^b   Hasselblad, Vic ^c   Albertsen, Peter C ^d   Bennett, Charles L ^b,e   Wilt, Timothy J ^f   Aronson, Naomi ^a  

^a Blue Cross and Blue Shield Association   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f VA MEDICAL CENTER   (United States)

Author keywords

Androgen antagonists; Diethylstilbestrol; Gonadorelin; Orchiectomy; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BUSERELIN; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE;

ARTICLE; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; HUMAN; META ANALYSIS; MONOTHERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 0037099723     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10647     Document Type: Article

References (56)

1. New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen
2. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival
3. Is there a best endocrine treatment of prostate cancer?
4. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: The argument against
5. Androgen withdrawal therapy: New perspectives in the treatment of prostate cancer
6. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: The argument for
7. Combined androgen blockade
8. Combined androgen blockade for the treatment of metastatic cancer of the prostate
9. History of LHRH agonist and combination therapy in prostate cancer
10. Combined androgen blockade in the treatment of advanced prostate cancer - An overview
11. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
12. Androgen deprivation strategies for metastatic prostate cancer
13. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens
14. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide
15. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
16. Assessing the quality of reports of randomised trials: Implications for the conduct of meta-analyses
17. Reporting standards and research strategies for controlled trials. Agenda for the editor
18. Design of clinical trials on prostate cancer
19. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer
20. A general approach to the meta-analysis of randomized clinical trials
21. Meta-analysis of multitreatment studies
22. Meta-analysis in clinical trials
23. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843
24. Combination treatment in M1 prostate cancer
25. Combination treatment versus LHRH alone in advanced prostatic cancer
26. Complete androgen blockade versus chemical castration in advanced prostatic cancer: Analysis of an Italian multicentre study
27. Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer
28. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
29. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate
30. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
31. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate
32. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate - An Australian multicentre trial
33. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma
34. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer
35. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization
36. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: A multicenter comparative study of two doses of the drug and of a placebo
37. Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer
38. Total androgen suppression: Experience from the Scandinavian Prostatic Cancer Group Study No. 2
39. Results of a 10-year randomised prospective study in metastasised prostate cancer
40. A randomized, controlled clinical trial of leuprolide and anandron (LA) vs leuprolide and placebo (LP) for advanced prostate cancer (D2cap)
41. Depot leuprorelin acetate alone or with nilutamide in the treatment of metastatic prostate carcinoma: Interim report of a multicenter, double-blind, placebo-controlled study
42. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer
43. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: Interim report of a multi-center, double-blind, placebo-controlled study
44. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer
45. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: A multicenter Italian study
46. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multi-center trial
47. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study
48. Quality of life (QOL) endpoints in advanced stage prostate cancer: A randomized, double blind study comparing flutamide to placebo in orchiectomized stage D2 prostate patients (PTS)
49. Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial
50. Health-related quality of life among patients with metastatic prostate cancer
51. Quality of life assessment in prostatic cancer
52. Quality of life in patients with prostatic cancer. A feasibility study
53. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer
54. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database